Alithea Genomics Raises CHF 1 Million in Seed Financing
- Alithea Genomics, a Lausanne, Switzerland-based leader in the field of RNA sequencing and transcriptomics analysis, raised CHF1M in Seed funding
- The round was led by Novalis Biotech Acceleration fund with participation of Swiss-based private investors
- Jan Van den Berghe, co-founder and managing director of Novalis Biotech, has been appointed to the board of directors
- The company intends to use the funds to expand the commercialization and scale-up of its new products, MERCURIUS™ BRB-seq and MERCURIUS™ Blood BRB-seq
- The BRB-seq technologies and kits enable researchers to discover novel biomarkers and essential data needed to develop new drugs at a fraction of the traditional cost and time
